Welcome!

.NET Authors: Lori MacVittie, Yeshim Deniz, Ivan Antsipau, Liz McMillan, Michael Bushong

News Feed Item

Synthesis Polypeptide Drug Market (Global and China) Research Report for 2012

DALLAS, November 30, 2012 /PRNewswire/ --

RnRMarketResearch.com adds new market research report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" to its store.

2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry is a professional and in-depth research report on China Synthesis Polypeptide Drug market. The report introduces Synthesis Polypeptide Drug with basic information including definition, classification, application, industry chain structure, industry overview and more. The research covers international market analysis, China domestic market analysis, Macroeconomic environment and economic situation analysis and influence, Synthesis Polypeptide Drug industry policy and plan, Synthesis Polypeptide Drug product specification, manufacturing process, product cost structure, etc. Statistics of China's key manufacturers of Synthesis Polypeptide Drug with their capacity production cost price profit production value gross margin and other details are also covered. In addition to the above said information, the study also presents products and their customers, application, capacity, market position, company contact information and other related information of these companies. The report also covers all these manufacturers' data and lists China Synthesis Polypeptide Drug capacity production capacity market share production market share supply demand shortage import export consumption etc data statistics, and then introduced China Synthesis Polypeptide Drug 2009-2013 capacity production price cost profit production value gross margin etc information. And also lists Synthesis Polypeptide Drug upstream raw materials equipments and Sharp Solarnstream clients alternative products survey analysis and Synthesis Polypeptide Drug marketing channels industry development trend and proposals. In the end, this report introduced Synthesis Polypeptide Drug new project SWOT analysis Investment feasibility analysis investment return analysis and also give related research conclusions and development trend analysis of China Synthesis Polypeptide Drug industry. In a word, it was a depth research report on China Synthesis Polypeptide Drug industry. And thanks to the support and assistance from Synthesis Polypeptide Drug industry chain related technical experts and marketing engineers during Research Team survey and interviews.

Buy your copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=57872

Table of Contents for the report "2012 Deep Research Report on Global and China Synthesis Polypeptide Drug Industry" cover:

Chapter One Synthesis Polypeptide Drug Industry Overview    1
1.1 Synthesis Polypeptide Drug Definition    1
1.2 Synthesis Polypeptide Drug Classification and Application    3
1.3 Professional Terms Interpretation    8
1.4 Synthesis Polypeptide Drug Industry Chain Structure    12
1.5 Synthesis Polypeptide Drug Industry Overview    14
Chapter Two Synthesis Polypeptide Drug International and China Market Analysis    16
2.1 Synthesis Polypeptide Drug Industry International Market Analysis    16
2.1.1 Synthesis Polypeptide Drug International Market Development History    16
2.1.2 Synthesis Polypeptide Drug Product and Technology Developments    18
2.1.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    25
2.1.4 Synthesis Polypeptide Drug International Key Countries Development Status    28
2.1.5 Synthesis Polypeptide Drug International Market Development Trend    30
2.2 Synthesis Polypeptide Drug China Market Analysis    33
2.2.1 Synthesis Polypeptide Drug China Market Development History    33
2.2.2 Synthesis Polypeptide Drug Product and Technology Developments    33
2.2.3 Synthesis Polypeptide Drug Competitive Landscape Analysis    35
2.2.4 Synthesis Polypeptide Drug China Key Regions Development Status    37
2.2.5 Synthesis Polypeptide Drug China Market Development Trend    37
2.3 Synthesis Polypeptide Drug International and China Market Comparison Analysis    42
Chapter Three Major Synthesis Polypeptide Drug Analysis    43
3.1 Immunity Regulating Medicine (Allergy Infection and Immune)    43
3.1.1 Glatiramer Injection (Glatiramer Acetate)    43
3.1.2 Thymalfasin for Injection    46
3.1.3 Thymopentin Injection    49
3.1.4 Thymopetidum Injection    53
3.1.5 Summary    55
3.2 Digestive System Drugs (Gastrointestinal Type)    57
3.2.1 Octreotide Acetate Injection    57
3.2.2 Somatostatin for Injection    61
3.3 Bone and Connective Tissue Types (Thyroid hormones Drug)    66
3.3.1 Salmon Calcitonin Injection    67
3.3.2 Elcatonin Injection    70
3.3.4 TerfparaLide Injectlon    72
3.4 Gynecologic or Obstetric Drug    76
3.4.1 Oxytocin Injection    76
3.4.2 Carbetocin Injection    81
3.4.3 Acetate Atosiban Injection    83
3.5 Tumor Drug (hCG)    86
3.5.1 Leuprorelin Acetate Microspheres for Injection    87
3.5.2 Goserelin Acetate    89
3.5.3 Triptorelin Acetate Injection    92
3.5.4 Chorionic Gonadotrophin for Injection    95
3.6 Urinary System Drug (Diabetes Insipidus)    98
3.6.1 Desmopressin Acetate Injection    98
3.6.2 Terlipressin for Injection    101
3.7 Metabolic Drug (Insulin and Other Hypoglycemic Agents)    105
3.7.1 Biosynthetic Glucagon for Injection    105
3.7.2 Exenatide Injection    106
Chapter Four Synthesis Polypeptide Drug Development Environmental Analysis    109
4.1 China's Macroeconomic Environment Analysis    109
4.1.1 China GDP Analysis    109
4.1.2 China CPI Analysis    111
4.2 European Economic Environmental Analysis and Impact    113
4.3 United States Economic Environmental Analysis and Impact    116
4.4 Japan Economic Environmental Analysis and Impact    119
4.5 Global Economic Environmental Analysis and Impact    120
4.5.1 Global Economic Environmental Analysis    120
4.5.2 Global Economic Influence    121
Chapter Five Synthesis Polypeptide Drug Development Policy and Plan    121
5.1 China Government Policy and Development Plan    121
5.2 Industry Policy and Standard    122
5.3 Technical Standard    125
5.4 Technology Replacement and R&D Trends    126
5.5 Hotspots and Influence    127
Chapter Six Synthesis Polypeptide Drug Manufacturing Process and Cost Structure    132
6.1 Synthesis Polypeptide Drug Manufacturing Process Overview    132
6.2 Synthesis Polypeptide Drug Manufacturing Process Analysis    135
6.3 Synthesis Polypeptide Drug Cost Structure Analysis    138
Chapter Seven 2009-2013 Synthesis Polypeptide Drug Productions Supply Sales Demand Market Status and Forecast    140
7.1 2009-2013 Synthesis Polypeptide Drug Capacity Production Overview    140
7.1.1 2009-2013 Global and China Synthesis Polypeptide Drug Capacity Production    140
7.1.2 2009-2013 Synthesis Polypeptide Drug Production Market Share    146
7.1.3 2009-2013 Synthesis Polypeptide Drug Demand Overview    152
7.1.4 2009-2013 Synthesis Polypeptide Drug Supply Demand and Shortage    152
7.1.5 2009-2013 Synthesis Polypeptide Drug Production Import Export Consumption    153
7.1.6 2009-2013 Synthesis Polypeptide Drug Cost Price Production Value Gross Margin    154
7.2 Different Type Synthesis Polypeptide Drug Sales and Market Scale Analysis    156
7.2.1Thymopentin Injection    156
7.2.2 Thymalfasin Injection    158
7.2.3 Calcitonin Injection    159
7.2.4 Somatostatin for Injection    161
7.2.5Octreotide Acetate Injection    162
7.2.6 Desmopressin Acetate Injection    163
7.3 Synthesis Polypeptide Drug Market Summary    165
Chapter Eight Synthesis Polypeptide Drug Key Manufacturers (Company Profiles)   170
8.1 Novartis    170
8.2 Merck Serono    176
8.3 Ferring Pharmaceuticals    181
8.4 Ipsen PHarma Biotech    188
8.5 Lilly    191
8.6 Asahi Kasei    195
8.7 AstraZeneca    199
8.8 SciClone Pharmaceuticals    203
8.9 Takeda    206
8.10 HYBIO Pharmaceutical Co.,Ltd (Shenzhen Stock:300199)    210
8.11 Hainan Zhonghe Pharmaceutical Co.,Ltd    215
8.12 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd    219
8.13 Beijing Yingu Century Pharmaceutical Co.,Ltd (Beijing Shiqiao Bio-Pharmaceutical Co.,Ltd)    224
8.14 Hainan Shuangcheng Pharmaceuticals Co.,Ltd    227
8.15 Livzon Pharmaceuticals Co.,Ltd (Livzon:000513)    234
8.16 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd    238
8.17 Chengdu Tiantaishan Pharmaceutical Co.,Ltd    242
8.18 Beijing Shuanglu Pharmaceutical Co.,Ltd    250
8.19 Yangzijiang Pharmaceutical Co.,Ltd    257
8.20 Changzhou Siyao Pharmaceutical Co.,Ltd    262
Chapter Nine Up and Down Stream Industry Analysis and Influence    267
9.1 Upstream Raw Materials Price Analysis and Influence    267
9.1 Upstream Equipments Market Analysis and Influence    269
9.3 Downstream Demand Analysis and Influence    270
9.4 Industry Policy Analysis and Influence    271
Chapter Ten Synthesis Polypeptide Drug Marketing Channels Analysis    272
10.1 Synthesis Polypeptide Drug Marketing Channels Status    272
10.1.1 Drugs Marketing Channel Developemnt History    272
10.1.1 Prescription Drug Marketing Development Status    273
10.2 Synthesis Polypeptide Drug Marketing Channels Management    274
10.3 Synthesis Polypeptide Drug Marketing Channels Establishment    275
10.4 Synthesis Polypeptide Drug Marketing Channels Development Trend    276
Chapter Eleven Synthesis Polypeptide Drug Industry Development Trend    278
11.1 2012-2016 Synthesis Polypeptide Drug Industry Development Trend    278
11.2 2012-2016 Market Potential Forecast    279
11.3 2012-2016 R&D Trend    280
11.3.1Polypeptide Drug Technical Development Status    280
11.3.2 Polypeptide Drug and Health Care Products Research and Manufacturing Overview    282
11.3.3 China Polypeptide Drug Development Direction and Prospect    283
11.4 2012-2016 Marketing Channels Change Trend    285
14.4.1 Prescription Drug Marketing Channels Change Trend    285
14.4.2 Prescription Drug Sales Method Five Trend    286
11.5 2012-2016 Competition Pattern Development Trends    288
Chapter Twelve Synthesis Polypeptide Drug Industry Development Proposals    289
12.1 Macroeconomic Development Countermeasures    289
12.2 New Firms Enter Market Strategy    290
12.2.1 New Business Entry Barriers    290
12.2.2 New Corporate Strategy    290
12.3 New Project Investment Proposal    293
12.4 Marketing Channel Strategy Proposals    294
12.5 Competitive Environment Strategy Proposals    296
12.5.1 Competitive Environment Analysis    296
12.5.2 Strategy Proposals    297
Chapter Thirteen Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    300
13.1 Synthesis Polypeptide Drug Project SWOT Analysis    300
13.2 Synthesis Polypeptide Drug New Project Investment Feasibility Analysis    302
13.2.1 Buildings    302
13.2.2 Investment    303
13.2.3 Project Schedule    303
13.2.4 Project Investment Return and Feasibility Analysis    304
Chapter Fourteen Synthesis Polypeptide Drug Industry Research Conclusions    304

 

List Of Tables and Figures

Figure Synthesis Polypeptide Process Flow    1
Figure Synthesis Polypeptide Drug Picture-Thymopentin Injection    2
Figure Polypeptide Applications on Health Care Food and Cosmetics Fields    4
Figure Polypeptide Drug Manufacturing Process Method    4
Table Synthesis Polypeptide Drug Classification and Application List    5
Table Synthesis Polypeptide Drug Product Name Use and Annual Sales Revenue (USD) List    6
Table Listed Polypeptide Drug Name Type Indication    6
Figure Pharmaceutical Industry Value Chain Structure    12
Figure Pharmaceutical Industry Industry Chain Structure    12
Figure Synthesis Polypeptide Drug Industry Chain Structure    13
Figure Synthesis Polypeptide Drug Industrialization System    13
Figure 2000-2011 China Pharmaceutical Industry Sales Revenue and Total Profit (100 Million RMB) and Growth Rate    14
Figure 2007-2015 China Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    15
Figure DNA Transcribed into RNA Diagram    17
Figure RNA Translated into Polypeptide Chains Molecular Diagram    18
Table Polypeptide Drug Three Manufacturing Methods    19
Figure 1984 Chemistry Nobel Prize Winner Robert Bruce Merrifield    20
Figure Polypeptide Solid Phase Synthesis Principle    20
Figure Solid Phase Polypeptide Synthesis    21
Figure United States CS Three Channel Full Automatic Polypeptide Synthetic Instrument    22
Figure Homemade CS136 Model Research Polypeptide Synthetic Instrument    23
Figure Large Scale Liquid Phase Synthesis of Polypeptide    24
Figure Thin Film Evaporator (for perishable goods Concentration)    24
Table Global 2008 Revenue More than 1 Billion Polypeptide Drug Brands List    25
Table Some Listed Polypeptide Drug Indication Classification    26
Figure Listed Polypeptide Drug Indication Classification Market Share    26
Figure 2004-2014 Global Pharmaceutical Sales Revenue (Billion USD) and Growth Rate    30
Figure 2009-2013 International Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    31
Table 2011 Some Polypeptide Drug Global Sales Revenue (100 Million USD)    31
Figure Each Year Enter Clinical Research Polypeptide Drug Quantity (Piece)    32
Table 17 Emerging Pharmaceutical Market Sizes (Billion USD)    38
Figure 2007-2015 China Pharmaceutical Sales Revenue (100 Million USD)    39
Figure 2009-2015 China Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    39
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Growth Rate    40
Figure 2009-2015 China Chemical Synthesis Polypeptide Drug Market Scale (100 Million RMB) and Proportion of China Total Polypeptide Drug Market Scale    41
Figure 2007-2009 China Chemical Synthesis Polypeptide Drug Types Market Share    41
Table Copaxone Neuron Structure Diagram    44
Table Thymalfasin for Injection (Thymalfasin a1) Suppliers List    48
Table 2010 Thymalfasin for Injection Key Products Price (RMB/Piece) List    49
Table Some Thymopentin Injection Suppliers List    51
Table Thymopentin Injection Hospital Purchase Price (RMB/Piece) List    52
Table Thymopetidum Injection Thymopentin Injection Thymalfasin Injection Comparison    56
Table Octreotide Acetate Injection Key Suppliers List    59
Table 2012 Hebei Province Octreotide Acetate Injection Bid Price List    60
Tale Somatostatin for Injection Key Suppliers List    64
Table Somatostatin for Injection Key Products Hospital Average Purchae Price List    64
Table 2012 Hebei Province Somatostatin for Injection Key Suppliers List    65
Table Salmon Calcitonin Injection Suppliers List    69
Table Salmon Calcitonin Injection/Nasal Spray Products Hospital Purchase Price List    69
Table Salmon Calcitonin Injection/Nasal spray Products Retail Price List    70
Table Elcatonin Injection Key Suppliers and Product Selling Price List    72
Figure TerfparaLide Injectlon-Forsteo Injection Pen Parts    75
Table 2011Q1 China Some Aproved New Drug Number, Specifications Suppliers and Indication    76
Table 2012 New Add Key Monitoring Drug Table--TerfparaLide Injectlon    76
Table Oxytocin Injection Key Suppliers List    78
Table Oxytocin Injection Suppliers Products Models List    80
Table Carbetocin Injection Suppliers List    83
Table Acetate Atosiban Injection Supplier Product Specification Price List    85
Table Leuprorelin Acetate Microspheres for Injection Suppliers Product Specification Price List    88
Table Triptorelin Acetate Injection Suppliers Product Specification Price List    94
Table Chorionic Gonadotrophin for Injection Suppliers Product Specifications List    97
Table 2011 Some Hormone Drugs Independent Pricing and Uniform Pricing Comparison    98
Table Desmopressin Acetate Injection Key Suppliers List    100
Table Desmopressin Acetate Injection Key Suppliers Forms Product Specifications and Bid Price List    101
Table Terlipressin for Injection Key Brands Manufacturers and Retail Prices    104
Table Biosynthetic Glucagon for Injection Suppliers and Retail Prices List    106
Table Exenatide Suppliers Product Specifications Retail Prices List    109
Figure 2007-2015 China Medical Industry Total Production Value (100 Million RMB) and Growth Rate    110
Table 2006-2011 China GDP (1000 Million RMB) and Growth Rate    110
Figure 2007-2011 China Medical Industry Total Value and Its Proportion of China Total GDP    111
Figure 2007-2015 China Individual Medical Expenditure (RMB)    112
Figure 2007-2015 China Health Expenditure Per Capita and National Medical Expenditure Comparison    112
Figure 2011-2016 China Population Growth and Aging Condition    113
Figure 2006-2011 Europe Several Countries PMI Trend    114
Figure United States CPI and PCE Growth Comparison    117
Figure United States Private Savings Rate Change and Net Export /GDP Proportion Change Trend    118
Figure United States Public Debt and Deficit Proportion of GDP    119
Figure Japan GDP and CPI Growth Rate Comparison    119
Figure 2009-2011 China Health Capital Investment (100 Million RMB)    122
Table China Pharmaceutical Industry All major Departments and Regulatory Functions    122
Table Pharmaceutical Industry main Laws and Regulations and Policies    125
Table 2009-2012 China Medical and Health System Reform Important Policy    128
Table 2009-2012 China Related Pharmaceutical Product Quality Supervision Policy    129
Table 2008-2012 China Development and Reform Commission Policy on Drug Price Management Policies    130
Figure PTIPolypeptide Synthetic Instruments Picture    133
Table Synthesis Polypeptide Drug Technology Processes List    133
Figure Polypeptide Pharmaceutical Raw Materials Manufacturing Process Flow    135
Figure Freeze Dried Powder Injection Manufacturing Process Flow    136
Figure Small Capacity Injection Manufacturing Process Flow    136
Figure Thymalfasin API Manufacturing Process Flow    137
Figure Thymalfasin Injection Manufacturing Process Flow    138
Figure International Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2011 China Synthesis Polypeptide Drug Cost Structure    139
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    140
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    141
Table 2009-2013 Global Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    141
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity and Total Capacity (10K Piece) List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Capacity Market Share List    142
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production and Total Production (10K Piece) List    143
Table 2009-2013 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share List    143
Figure 2009-2013 Global Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    144
Table 2009-2013 Global Synthesis Polypeptide Drug Capacity Utilization Rate List    144
Figure 2009-2013 China Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    145
Table 2009-2013 China Synthesis Polypeptide Drug Capacity Utilization Rate List    145
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales (10K Piece) Top20 List    146
Table 2009-2013 Key Manufacturers Synthesis Polypeptide Drug China Sales Top20 Market Share List    147
Table 2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue (100 Million RMB) Top10 List    147
Table 2008-2010 Key Manufacturers Synthesis Polypeptide Drug China Sales Revenue Top10 Market Share List    148
Figure 2011 Key Manufacturers Synthesis Polypeptide Drug China Sales Market Share    149
Figure 2012 Key Manufacturers Synthesis Polypeptide Drug China Sales TOP20 Market Share    150
Figure 2011 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Figure 2012 China Key Manufacturers Synthesis Polypeptide Drug Production Market Share    151
Table 2009-2013 Global Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Demand (10K Piece) and Growth Rate    152
Table 2009-2013 China Synthesis Polypeptide Drug Supply Demand and Shortage (10K Piece)    153
Table 2009-2013 Nine Foreign Enterprises Synthesis Polypeptide Drug China Sales (10K Piece) List    153
Table 2009-2013 China Synthesis Polypeptide Drug Production Import Export Consumption (10K Piece) List    154
Table 2007-2009 China Synthesis Polypeptide Drug Price (RMB/Piece) Distribution    154
Table 2009-2011 Hainan Shuangcheng Pharmaceuticals Some Synthesis Polypeptide Drug Price Cost (RMB/Piece) Gross Margin List    155
Table 2009-2013 China Synthesis Polypeptide DrugProduction (10K Piece) Price Cost Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    155
Figure 2011 China Synthesis Polypeptide Drug Market Share by Different Type Drug    156
Figure 2008-2014 China Thymopentin Injection Market Scale (100 Million RMB) and Growth Rate    157
Figure 2008-2014 China Thymopentin Injection Sales (10K Piece) and Growth Rate    157
Figure 2008-2014 China Thymalfasin Injection Market Scale (100 Million RMB) and Growth Rate    158
Figure 2008-2014 China Thymalfasin Injection Sales (10K Piece) and Growth Rate    159
Figure 2008-2014 China Calcitonin Injection Market Scale (100 Million RMB) and Growth Rate    160
Figure 2008-2014 China Calcitonin Injection Sales (10K Piece) and Growth Rate    160
Figure 2008-2014 China Somatostatin for Injection Market Scale (100 Million RMB) and Growth Rate    161
Figure 2008-2014 China Somatostatin for Injection Sales (10K Piece) and Growth Rate    162
Figure 2008-2014 China Octreotide Acetate Injection Market Scale (100 Million RMB) and Growth Rate    163
Figure 2008-2014 China Octreotide Acetate Injection Sales (10K Piece) and Growth Rate    163
Figure 2008-2014 China Desmopressin Acetate Injection Market Scale (100 Million RMB) and Growth Rate    164
Figure 2008-2014 China Desmopressin Acetate Injection Sales (10K Piece) and Growth Rate    164
Table 2009-2011 China Chemical Synthesis Polypeptide Drug Injection Distribution List    165
Figure 2010 Global Polypeptide Drug Market Structure by Treatment Class    165
Table Research or Listed Polypeptide Drugs List    166
Figure 1990-2010 China Resident Three Types of Chronic Disease Prevalence (1/100K) Change Trend    167
Figure 2010 China Synthesis Polypeptide Drug Hospital Terminal Sales Market Share Distribution    168
Figure 2010 China Synthesis Polypeptide Drug Top10 Manufacturers Sales Revenue (100 Million RMB)    168
Figure China Synthesis Polypeptide Drug Prices Distribution    169
Figure Use Me-Too Model Developed Polypeptide Drug List    169
Table Novartis Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    170
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Octreotide Acetate Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--Somatostatin Acetate for Injection    173
Figure Novartis China Market Sales Synthesis Polypeptide Drug--salmon Calcitonin Nasal Spray    174
Table 2009-2013 Novartis Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    174
Figure 2009-2013 Novartis Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    175
Table Merck Serono Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    176
Figure Merck Serono Synthesis Polypeptide Drug--Recombinant Human Follitropin Alfa Solution for Injection    178
Figure Merck Serono Synthesis Polypeptide Drug--Somatostatin for Injection    179
Figure Merck Serono Synthesis Polypeptide Drug--Gonadorelin for Injection    179
Table 2009-2013 Merck Serono Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    180
Figure 2009-2013 Merck Serono Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    181
Table Ferring Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    182
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Minirin    183
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Decapeptyl    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Pentasa    184
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Glypressin    185
Figure Ferring Pharmaceuticals China Market Sales Synthesis Polypeptide Drug--Octostim    186
Table 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    186
Figure 2009-2013 Ferring Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    188
Table Ipsen PHarma Biotech Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    188
Figure Ipsen PHarma Biotech  Synthesis Polypeptide Drug--Triptorelin Acetate for Injection    190
Table 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    190
Figure 2009-2013 Ipsen PHarma Biotech Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    191
Table Lilly Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    192
Figure Lilly Some China Listed Synthesis Polypeptide Drug List    194
Table 2009-2013 Lilly Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    194
Figure 2009-2013 Lilly Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    195
Table Asahi Kasei Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    195
Figure Asahi Kasei Synthesis Polypeptide Drug--Elcatonin Injection    198
Table 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    198
Figure 2009-2013 Asahi Kasei Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    199
Table AstraZeneca Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    199
Figure AstraZeneca China Selling Synthesis Polypeptide Drug-Goserelin Acetate Slow Release Implantation Agent    201
Table 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    202
Figure 2009-2013 Jiangsu AstraZeneca Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    203
Table SciClone Pharmaceuticals Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    204
Figure SciClone Pharmaceuticals Synthesis Polypeptide Drug-- Thymopetidum α1 Injection    205
Table 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    205
Figure 2009-2013 SciClone Pharmaceuticals Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    206
Table Takeda Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    206
Figure Takeda--Leuprorelin Acetate Microspheres for Injection    208
Table 2009-2013 Takeda Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    209
Figure 2009-2013 Takeda Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    209
Table HYBIO Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    210
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug    211
Table 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    213
Figure 2009-2013 HYBIO Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    215
Table Hainan Zhonghe Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    216
Figure Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug产品    217
Table 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    217
Figure 2009-2013 Hainan Zhonghe Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    219
Table Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    219
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymalfasin Injection    221
Figure Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    222
Table 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    222
Figure 2009-2013 Sichuan Chengdu Diao Pharmaceutical Group Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    223
Table Beijing Yingu Century Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    224
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Nasal Spray    225
Figure Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    226
Table 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    226
Figure 2009-2013 Beijing Yingu Century Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    227
Table Hainan Shuangcheng Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    228
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug--Thymalfasin Injection(基泰)    229
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    231
Figure Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection (双成可维)    232
Table 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    233
Figure 2009-2013 Hainan Shuangcheng Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    234
Table Livzon Pharmaceuticals Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    234
Figure Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug    236
Table 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    236
Figure 2009-2013 Livzon Pharmaceuticals Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    238
Table Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    239
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Thymopentin Injection    240
Figure Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug--Somatostatin for Injection    240
Table 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    241
Figure 2009-2013 Wuhan Hualong Bio-Chemical Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    242
Table Chengdu Tiantaishan Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    242
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    244
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    246
Figure Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Octreotide Acetate Injection    247
Table 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    248
Figure 2009-2013 Chengdu Tiantaishan Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    249
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    250
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    251
Figure Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Salmon Calcitonin Injection    252
Table Beijing Shuanglu Pharmaceutical Co.,Ltd Thymopentin Injection Price List    253
Table 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    256
Figure 2009-2013 Beijing Shuanglu Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    257
Table Yangzijiang Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    257
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Somatostatin for Injection    259
Figure Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug-Thymopentin Injection    260
Table 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    260
Figure 2009-2013 Yangzijiang Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    261
Table Changzhou Siyao Pharmaceutical Co.,Ltd Company Information Table (Products Applications Manufacturing Base Location Capacity Expansion Plan Market Position Contact Information etc 13 Items)    262
Figure Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Pharmaceutical Raw Materials List    264
Table Changzhou Siyao Pharmaceutical Co.,Ltd Chemical Raw Materials Intermediates List    265
Table 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Production (10K Piece) Cost Price Gross (RMB/Piece) Production Value (10K RMB) Gross Margin List    266
Figure 2009-2013 Changzhou Siyao Pharmaceutical Co.,Ltd Synthesis Polypeptide Drug Capacity Production (10K Piece) and Growth Rate    266
Table Synthesis Polypeptide Drug Project Key Equipments and Price (10K RMB)    269
Table Synthesis Polypeptide Drug Project Equipments List and Price (10K RMB)    270
Table Drugs Manufacturing Enterprise Specialized Academic Promotion Organization Frame    276
Figure Synthesis Polypeptide Drug Industry Entry Barriers List    293
Table 2012 China Synthesis Polypeptide Drug New Project SWOT Analysis    300
Table 2012 China Synthesis Polypeptide Drug New Project Buildings List    302
Table 2012 China Synthesis Polypeptide Drug New Project Investments (10K RMB) List    303
Table Synthesis Polypeptide Drug New Project Investment Return and Feasibility Analysis    304

Browse more reports on the Pharmaceuticals Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals.

Explore newly published market research reports on other industries and for different geographies @ http://www.rnrmarketresearch.com/latest_reports.

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online market research reports library of 175,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.

Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
[email protected]
Explore more Industry reports @ http://www.marketreportsonline.com/.


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

@ThingsExpo Stories
Software AG helps organizations transform into Digital Enterprises, so they can differentiate from competitors and better engage customers, partners and employees. Using the Software AG Suite, companies can close the gap between business and IT to create digital systems of differentiation that drive front-line agility. We offer four on-ramps to the Digital Enterprise: alignment through collaborative process analysis; transformation through portfolio management; agility through process automation and integration; and visibility through intelligent business operations and big data.
There will be 50 billion Internet connected devices by 2020. Today, every manufacturer has a propriety protocol and an app. How do we securely integrate these "things" into our lives and businesses in a way that we can easily control and manage? Even better, how do we integrate these "things" so that they control and manage each other so our lives become more convenient or our businesses become more profitable and/or safe? We have heard that the best interface is no interface. In his session at Internet of @ThingsExpo, Chris Matthieu, Co-Founder & CTO at Octoblu, Inc., will discuss how these devices generate enough data to learn our behaviors and simplify/improve our lives. What if we could connect everything to everything? I'm not only talking about connecting things to things but also systems, cloud services, and people. Add in a little machine learning and artificial intelligence and now we have something interesting...
Last week, while in San Francisco, I used the Uber app and service four times. All four experiences were great, although one of the drivers stopped for 30 seconds and then left as I was walking up to the car. He must have realized I was a blogger. None the less, the next car was just a minute away and I suffered no pain. In this article, my colleague, Ved Sen, Global Head, Advisory Services Social, Mobile and Sensors at Cognizant shares his experiences and insights.
We are reaching the end of the beginning with WebRTC and real systems using this technology have begun to appear. One challenge that faces every WebRTC deployment (in some form or another) is identity management. For example, if you have an existing service – possibly built on a variety of different PaaS/SaaS offerings – and you want to add real-time communications you are faced with a challenge relating to user management, authentication, authorization, and validation. Service providers will want to use their existing identities, but these will have credentials already that are (hopefully) irreversibly encoded. In his session at Internet of @ThingsExpo, Peter Dunkley, Technical Director at Acision, will look at how this identity problem can be solved and discuss ways to use existing web identities for real-time communication.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. It also ensured scalability and better service for customers, including MUY! Companies, one of the country's largest franchise restaurant companies with 232 Pizza Hut locations. This is one example of WebRTC adoption today, but the potential is limitless when powered by IoT. Attendees will learn real-world benefits of WebRTC and explore future possibilities, as WebRTC and IoT intersect to improve customer service.
From telemedicine to smart cars, digital homes and industrial monitoring, the explosive growth of IoT has created exciting new business opportunities for real time calls and messaging. In his session at Internet of @ThingsExpo, Ivelin Ivanov, CEO and Co-Founder of Telestax, will share some of the new revenue sources that IoT created for Restcomm – the open source telephony platform from Telestax. Ivelin Ivanov is a technology entrepreneur who founded Mobicents, an Open Source VoIP Platform, to help create, deploy, and manage applications integrating voice, video and data. He is the co-founder of TeleStax, an Open Source Cloud Communications company that helps the shift from legacy IN/SS7 telco networks to IP-based cloud comms. An early investor in multiple start-ups, he still finds time to code for his companies and contribute to open source projects.
The Internet of Things (IoT) promises to create new business models as significant as those that were inspired by the Internet and the smartphone 20 and 10 years ago. What business, social and practical implications will this phenomenon bring? That's the subject of "Monetizing the Internet of Things: Perspectives from the Front Lines," an e-book released today and available free of charge from Aria Systems, the leading innovator in recurring revenue management.
The Internet of Things will put IT to its ultimate test by creating infinite new opportunities to digitize products and services, generate and analyze new data to improve customer satisfaction, and discover new ways to gain a competitive advantage across nearly every industry. In order to help corporate business units to capitalize on the rapidly evolving IoT opportunities, IT must stand up to a new set of challenges.
There’s Big Data, then there’s really Big Data from the Internet of Things. IoT is evolving to include many data possibilities like new types of event, log and network data. The volumes are enormous, generating tens of billions of logs per day, which raise data challenges. Early IoT deployments are relying heavily on both the cloud and managed service providers to navigate these challenges. In her session at 6th Big Data Expo®, Hannah Smalltree, Director at Treasure Data, to discuss how IoT, Big Data and deployments are processing massive data volumes from wearables, utilities and other machines.
All major researchers estimate there will be tens of billions devices – computers, smartphones, tablets, and sensors – connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. With major technology companies and startups seriously embracing IoT strategies, now is the perfect time to attend @ThingsExpo in Silicon Valley. Learn what is going on, contribute to the discussions, and ensure that your enterprise is as "IoT-Ready" as it can be!
P2P RTC will impact the landscape of communications, shifting from traditional telephony style communications models to OTT (Over-The-Top) cloud assisted & PaaS (Platform as a Service) communication services. The P2P shift will impact many areas of our lives, from mobile communication, human interactive web services, RTC and telephony infrastructure, user federation, security and privacy implications, business costs, and scalability. In his session at Internet of @ThingsExpo, Erik Lagerway, Co-founder of Hookflash, will walk through the shifting landscape of traditional telephone and voice services to the modern P2P RTC era of OTT cloud assisted services.
While great strides have been made relative to the video aspects of remote collaboration, audio technology has basically stagnated. Typically all audio is mixed to a single monaural stream and emanates from a single point, such as a speakerphone or a speaker associated with a video monitor. This leads to confusion and lack of understanding among participants especially regarding who is actually speaking. Spatial teleconferencing introduces the concept of acoustic spatial separation between conference participants in three dimensional space. This has been shown to significantly improve comprehension and conference efficiency.
The Internet of Things is tied together with a thin strand that is known as time. Coincidentally, at the core of nearly all data analytics is a timestamp. When working with time series data there are a few core principles that everyone should consider, especially across datasets where time is the common boundary. In his session at Internet of @ThingsExpo, Jim Scott, Director of Enterprise Strategy & Architecture at MapR Technologies, will discuss single-value, geo-spatial, and log time series data. By focusing on enterprise applications and the data center, he will use OpenTSDB as an example to explain some of these concepts including when to use different storage models.
SYS-CON Events announced today that Gridstore™, the leader in software-defined storage (SDS) purpose-built for Windows Servers and Hyper-V, will exhibit at SYS-CON's 15th International Cloud Expo®, which will take place on November 4–6, 2014, at the Santa Clara Convention Center in Santa Clara, CA. Gridstore™ is the leader in software-defined storage purpose built for virtualization that is designed to accelerate applications in virtualized environments. Using its patented Server-Side Virtual Controller™ Technology (SVCT) to eliminate the I/O blender effect and accelerate applications Gridstore delivers vmOptimized™ Storage that self-optimizes to each application or VM across both virtual and physical environments. Leveraging a grid architecture, Gridstore delivers the first end-to-end storage QoS to ensure the most important App or VM performance is never compromised. The storage grid, that uses Gridstore’s performance optimized nodes or capacity optimized nodes, starts with as few a...
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace. These technological reforms have not only changed computers and smartphones, but are also changing the data processing model for all information devices. In particular, in the area known as M2M (Machine-To-Machine), there are great expectations that information with a new type of value can be produced using a variety of devices and sensors saving/sharing data via the network and through large-scale cloud-type data processing. This consortium believes that attaching a huge number of devic...
Innodisk is a service-driven provider of industrial embedded flash and DRAM storage products and technologies, with a focus on the enterprise, industrial, aerospace, and defense industries. Innodisk is dedicated to serving their customers and business partners. Quality is vitally important when it comes to industrial embedded flash and DRAM storage products. That’s why Innodisk manufactures all of their products in their own purpose-built memory production facility. In fact, they designed and built their production center to maximize manufacturing efficiency and guarantee the highest quality of our products.
All major researchers estimate there will be tens of billions devices - computers, smartphones, tablets, and sensors - connected to the Internet by 2020. This number will continue to grow at a rapid pace for the next several decades. Over the summer Gartner released its much anticipated annual Hype Cycle report and the big news is that Internet of Things has now replaced Big Data as the most hyped technology. Indeed, we're hearing more and more about this fascinating new technological paradigm. Every other IT news item seems to be about IoT and its implications on the future of digital business.
Can call centers hang up the phones for good? Intuitive Solutions did. WebRTC enabled this contact center provider to eliminate antiquated telephony and desktop phone infrastructure with a pure web-based solution, allowing them to expand beyond brick-and-mortar confines to a home-based agent model. Download Slide Deck: ▸ Here
BSQUARE is a global leader of embedded software solutions. We enable smart connected systems at the device level and beyond that millions use every day and provide actionable data solutions for the growing Internet of Things (IoT) market. We empower our world-class customers with our products, services and solutions to achieve innovation and success. For more information, visit www.bsquare.com.
With the iCloud scandal seemingly in its past, Apple announced new iPhones, updates to iPad and MacBook as well as news on OSX Yosemite. Although consumers will have to wait to get their hands on some of that new stuff, what they can get is the latest release of iOS 8 that Apple made available for most in-market iPhones and iPads. Originally announced at WWDC (Apple’s annual developers conference) in June, iOS 8 seems to spearhead Apple’s newfound focus upon greater integration of their products into everyday tasks, cross-platform mobility and self-monitoring. Before you update your device, here is a look at some of the new features and things you may want to consider from a mobile security perspective.